This setback prompted us to explore whether bypassing the BBB via the CSF microcirculation pathway could lead to improved brain exposure, thereby potentially reviving interest in the use of ADCs for the treatment of EGFR+ GBM tumors. Here, EGFR is linked to glioblastoma.